CTOR (Citius Oncology) Tariff Resilience Score: 7/10 (As of Jun. 27, 2026)


CTOR Citius Oncology Inc CTOR
10 GF Score
Price $0.63
! 2 Warning Signs
View Full Analysis

What is Citius Oncology Tariff Resilience Score?

Citius Oncology CTOR -6.07% 10 Tariff Resilience Score is 7 as of Jun. 27, 2026. GuruFocus rates CTOR with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 1,031 Drug Manufacturers companies, Citius Oncology ranks better than 97.09% on this metric.

Citius Oncology has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Citius Oncology has Citius Oncology Inc has moderate resilience to tariffs due to its focus on domestic markets and limited international supply chain dependencies. The company has not faced significant impacts from past tariffs and has some pricing power in its specialized market.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Citius Oncology might have Highly Resilient.

Citius Oncology  (NAS:CTOR) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Citius Oncology Tariff Resilience Score Related Terms

CTOR vs INCR, BGM, CPIX: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Citius Oncology's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Citius Oncology Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Citius Oncology's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Citius Oncology's Tariff Resilience Score falls into.


CTOR
10GF Score
Citius Oncology Inc CTOR
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Citius Oncology (CTOR) has a Tariff Resilience Score of 7 as of Jun. 27, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Citius Oncology ranks #30 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is Citius Oncology's Tariff Resilience Score too high?
Citius Oncology's current Tariff Resilience Score is 7. Based on the distribution chart, Citius Oncology ranks #30 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Citius Oncology has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Citius Oncology's Tariff Resilience Score compare to INCR and BGM?
According to the Drug Manufacturers industry distribution chart, Citius Oncology ranks #30 out of 1031 companies for Tariff Resilience Score. This places Citius Oncology in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Citius Oncology's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Oncology stock overvalued right now?
Citius Oncology (CTOR) has a current Tariff Resilience Score of 7. The current Tariff Resilience Score is 7. Citius Oncology's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Citius Oncology (CTOR), the current Tariff Resilience Score is 7 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Citius Oncology Business Description

Address 11 Commerce Drive, First Floor, Cranford, NY, USA, 07016
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
10GF Score

Get the complete analysis for CTOR

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.63
Price